The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia.
Shlomzion AumannAdir ShaulovArnon HaranNoa Gross Even-ZoharVladimir VainsteinBoaz NachmiasPublished in: International journal of molecular sciences (2022)
Venetoclax, a B-cell lymphoma (BCL-2) inhibitor, in combination with hypomethylating agents has become the new standard of care in elderly and unfit patients with acute myeloid leukemia, with significantly improved overall survival and quality of life. Studies of venetoclax combined with high-dose chemotherapy are emerging with evidence of higher rates of molecular remission. Recently, a growing number of publications bring forth the use of venetoclax in patients with acute lymphoblastic leukemia (ALL). In the current review, we present the biological rationale of BCL-2 inhibition in ALL, how the interplay of BH3 proteins modulate the response and the current clinical experience with various combinations.
Keyphrases
- acute lymphoblastic leukemia
- chronic lymphocytic leukemia
- allogeneic hematopoietic stem cell transplantation
- acute myeloid leukemia
- high dose
- healthcare
- palliative care
- diffuse large b cell lymphoma
- quality improvement
- locally advanced
- squamous cell carcinoma
- pain management
- disease activity
- rheumatoid arthritis
- free survival